This Week in Cardiology — May 28, 2026

Welcome to This Week in Cardiology. This week we're covering 10 notable papers spanning heart failure management, new insights into antithrombotic and lipid-lowering drugs, important findings in arrhythmia, and the practicalities of clinical practice… This week's papers: 1. Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis. — JAMA 2026 2. Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis. — European heart journal 2026 3. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. — The New England journal of medicine 2026 4. Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. — JAMA cardiology 2026 5. Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial. — JAMA cardiology 2026 6. Clinical Diagnosis of Calcium Release Deficiency Syndrome in a Family With Sudden Cardiac Death. — JAMA cardiology 2026 7. Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial. — Journal of the American College of Cardiology 2026 8. Roadmap to Revitalizing Academic Cardiovascular Medicine: A Perspective From the Association of Professors of Cardiology (APC) Emerging Leaders Group. — Journal of the American College of Cardiology 2026 9. Arrhythmias, dementia risk, and neurodegeneration: a cohort study. — European heart journal 2026 10. Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction. — Cardiovascular research 2026 Listen at https://audioscholar.cc/episode/zk6xvfkxyu